IP Library Granted Patent US 9,192,650
Granted Patent B2
US 9,192,650 · App. 13/599,699 · Granted Nov 24, 2015

Methods of inhibiting photoreceptor apoptosis by eliciting the Faim2 antiapoptotic pathway

Inventors: David N. Zacks (Ann Arbor, MI); Cagri Besirli (Ann Arbor, MI)
Assignee: The Regents of the University of Michigan
A61K38/1709A01K67/027A61K48/0066A61K48/0075A01K2207/30A01K2227/105A01K2267/03A61K48/00C07H21/04C07K14/705C12N15/861
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,192,650
App. No.
13/599,699
Granted
Nov 24, 2015
Kind
B2
Abstract

The present invention provides compositions and methods to prevent apoptosis. In particular, provided herein are compositions and methods which prevent FAS-mediated photoreceptor apoptosis.

Claims (13)

1. A method of increasing photoreceptor survival comprising administering to the retina of a subject a nucleic acid encoding a polypeptide or peptide with at least 90% identity to SEQ ID NO: 1 (wild-type Fas apoptotic inhibitory molecule 2 (Faim2)) that elicits the Faim2 antiapoptotic pathway.

2. The method of claim 1 , wherein said increasing photoreceptor survival comprises inhibiting photoreceptor apoptosis.

3. The method of claim 2 , wherein said photoreceptor apoptosis comprises FAS-mediated photoreceptor apoptosis.

4. The method of claim 1 , wherein said polypeptide or peptide is full-length of Faim2.

5. The method of claim 1 , wherein said polypeptide or peptide is a fragment of full-length Faim2.

6. The method of claim 5 , where said polypeptide or peptide maintains the anti-apoptotic and/or photoreceptor protective functionality of full-length Faim2.

7. The method of claim 1 , wherein said nucleic acid is administered to a population of cells.

8. The method of claim 1 , wherein said subject suffers from an ocular condition, disease, or condition or disease affecting ocular health selected from the list consisting of retinal detachment, macular degeneration, retinitis pigmentosa, ocular inflammation, autoimmune retinopathy, trauma, cancer, tumor, uveitis, hereditary retinal degeneration, diabetic retinopathy, choroidal neovascularization, retinal ischemia, pathologic myopia, angioid streaks, macular edema, or central serous chorioretinopathy.

9. The method of claim 1 , wherein said nucleic acid is within a genetic vector.

10. The method of claim 9 , wherein said genetic vector further comprises a promoter that enables increased expression of the polypeptide or peptide encoded by the nucleic acid.

11. The method of claim 10 , wherein said genetic vector is an adeno-associated virus (AAV) vector.

12. The method of claim 1 , wherein said nucleic acid is administered subretinally.

13. The method of claim 12 , wherein said nucleic acid is administered to photoreceptor cells.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2012
From: ZACKS, DAVID N.; BESIRLI, CAGRI
To: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Reel/Frame 029237/0948 →
CONFIRMATORY LICENSE Recorded Sep 18, 2012
From: UNIVERSITY OF MICHIGAN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029002/0992 →
Continuity (2)
Provisional Application 61529106 · Aug 30, 2011
Related Publication 20130053328A1 · Feb 28, 2013